Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
144.99 ^USD	+0.42%		+0.74%	+18.13%

Mar. 11	Gilead Sciences, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11:00 AM
Mar. 10	Gilead Sciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM

Press Releases

Mar. 09	Bringing It Home - South Africa is Leading the Charge to Make Anti-HIV jab for Africa	AQ
Mar. 02	Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia	BU
Feb. 25	Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy	BU
Feb. 23	Gilead Sciences : to-Present-at-Upcoming-Investor-Conferences	PU
Feb. 23	Gilead Sciences to Present at Upcoming Investor Conferences	BU
Feb. 23	Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel	BU
Feb. 21	A long-acting HIV drug arrives in Zimbabwe for some at highest risk	AQ
Feb. 17	Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options	BU
Feb. 10	Gilead Sciences : Q4 2025 Earnings Presentation	PU
Feb. 10	Gilead Sciences : Fourth Quarter 2025 Resource Book	PU
Feb. 10	Gilead Sciences : Fourth Quarter 2025 Prepared Remarks	PU
Feb. 10	Gilead Sciences : Fourth Quarter 2025 Summary of Remarks	PU
Feb. 10	Gilead Sciences : Fourth Quarter 2025 Supplementary Information	PU
Feb. 10	Gilead: Q4 Earnings Snapshot	AQ
Feb. 10	Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend	BU
Feb. 10	Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results	BU
Feb. 06	FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma	BU
Jan. 27	Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026	BU
Jan. 21	New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer	BU
Jan. 09	Gilead Sciences : Fourth Quarter 2025 Estimated Acquired IPR&D	PU
Dec. 22	Gilead Sciences to Present at Upcoming Investor Conference	BU
Dec. 22	Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes	BU
Dec. 22	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans	AQ
Dec. 19	Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans	BU
Dec. 18	Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance	BU